Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of Alzheimer’s disease
3.2.1.2 Technological advancements in diagnostics
3.2.1.3 Growing awareness and diagnosis rates
3.2.1.4 Favorable reimbursement policies
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost of drug development
3.2.2.2 High failure rate in clinical trials
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 By stage of disease
3.7 Porter's analysis
3.8 PESTEL analysis
3.9 Future market trends
3.10 GAP analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Vendor matrix analysis
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Cholinesterase inhibitors
5.3 NMDA receptor antagonist
5.4 Combination drugs
5.5 Glutamate inhibitors
5.6 MAO inhibitors
5.7 Other drug classes
Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Oral
6.3 Injectable
6.4 Transdermal patch
Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Hospital pharmacy
7.3 Retail pharmacy
7.4 Online pharmacy
Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Spain
8.3.5 Italy
8.3.6 Netherlands
8.3.7 Rest of Europe
8.4 Asia Pacific
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Australia
8.4.5 South Korea
8.4.6 Rest of Asia Pacific
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Argentina
8.5.4 Rest of Latin America
8.6 Middle East and Africa
8.6.1 South Africa
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Rest of Middle East and Africa
Chapter 9 Company Profiles
9.1 AbbVie Inc.
9.2 Amgen Inc.
9.3 AstraZeneca
9.4 Biogen
9.5 Cipla Inc.
9.6 Daiichi Sankyo Company, Limited
9.7 Eisai Co., Ltd.
9.8 Eli Lilly and Company
9.9 H. Lundbeck A/S
9.10 Merck & Co., Inc.
9.11 Novartis AG
9.12 Otsuka Pharmaceutical Co., Ltd.
9.13 Pfizer, Inc.
9.14 Sanofi
9.15 Sun Pharmaceutical Industries Ltd.
